Welcome to our dedicated page for Greenbrook TMS news (Ticker: GBNH), a resource for investors and traders seeking the latest updates and insights on Greenbrook TMS stock.
Greenbrook TMS Inc. (NASDAQ: GBNH) delivers innovative mental health solutions through its network of 130 treatment centers, specializing in Transcranial Magnetic Stimulation (TMS) therapy and Spravato® for depression. This page provides essential updates on corporate developments, clinical advancements, and strategic initiatives shaping this mental health leader.
Investors and healthcare professionals will find timely information on financial restructuring efforts, leadership appointments like recent board member Juliana Elstad, and operational milestones including over 1.3 million treatments administered. Our curated news collection covers earnings reports, partnership announcements, and treatment efficacy updates while maintaining compliance with financial disclosure standards.
Discover how Greenbrook combines clinical expertise with business innovation through its FDA-cleared therapies and strategic financing agreements. Bookmark this page for ongoing insights into corporate governance changes, treatment accessibility improvements, and industry recognition of non-invasive depression therapies.
FAQ
What is the market cap of Greenbrook TMS (GBNH)?
